Imagenetix Also Introduces New Ear, Nose and Throat Product – BioGuard(TM) – BioGuard(TM) Promotes Protection for the Entire Family

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News) announced that InflameAway Celadrin® extra strength soft gels for joint health are currently available at the nation’s number one drug chain, the number one and number two supermarket stores and the number one club warehouse store. This retail distribution provides a platform for future retail gains as well as additional product launches, including a 100 count value size.

Going forward, Imagenetix plans to expand its current successful 15 and 30 second television ad spots for InflameAway Celadrin® to national audiences via cable as its primary driver of retail turnover. Starting August 10th, InflameAway Celadrin® can be seen on networks such as FOX News, CNN, USA and Hallmark. The spots will emphasize the theme of InflameAway Celadrin® being “6x Faster and More Effective” than Glucosamine and Chondroitin in promoting joint health. The campaign will also include compelling “actual user” testimonials as further evidence of brand performance and efficacy. This consumer campaign is intended to position InflameAway Celadrin® for rapid acceptance during the balance of this year and into 2010 – with the goal of obtaining loyal advocates of InflameAway Celadrin®. Repeat customers, product compliance and beneficial results are core strengths of the InflameAway Celadrin® brand.

Imagenetix, Inc. also announced today that BioGuard(TM) will be introduced during October 2009 in the Pacific Northwest Region in the nation’s number one club warehouse. BioGuard(TM) lives up to the Imagenetix standard of being both novel and scientifically backed as well as a product that uniquely enhances human health. Through published clinical studies, BioGuard(TM) has been shown to promote protection for the ear, nose and throat, and may be used by the entire family. BioGuard(TM) “melt tabs” are a one per day tablet offered in a pleasant all natural strawberry flavor.

Listen to the interview below.

Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health, announced today that its Director of Research and Development, Dr. Robert Hesslink, discussed 1-TDC and periodontal disease on Bloomberg Radio.

The company also recently announced the publication of an article on its Boston University study in the July issue of the Journal of Periodontology.

In the recent study, 1-TDC was applied to the gum line using the rabbit periodontitis model developed by Boston University investigators. The study results showed that 1-TDC stopped the progression of periodontal disease with a significant improvement and restoration in tissue and bone health compared to the placebo group.

SAN DIEGO, Aug. 13 /PRNewswire-FirstCall/ — On June 22, 2009, Cetyl Max/Flexadren mischaracterized certain facts associated with the settlement between those entities and Imagenetix (OTC Bulletin Board: IAGX – News). Both companies extend their apologies to Imagenetix and to those who may have been affected by the mischaracterization.

SAN DIEGO, Aug. 12 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today the publication of a second study conducted on its proprietary compound, 1-TDC, for the treatment of periodontal disease. Dr. Hatice Hasturk, D.D.S., Ph.D. from Boston University, Department of Periodontology and Oral Biology, led the investigative team. The study was published in the July issue of The Journal of Periodontology and is also available online at: http://www.joponline.org/loi/jop (J Periodontal 2009; 80(7):1103-13).

In the recent study, 1-TDC was applied to the gum line using the rabbit periodontitis model developed by Boston University investigators. The study results show that 1-TDC stopped the progression of periodontal disease with a significant improvement and restoration in tissue and bone health compared to the placebo group. “The results of this experiment are very exciting and demonstrate the great promise that 1-TDC offers in the treatment of periodontal disease,” stated Dr. Hasturk. “These findings clearly demonstrate that 1-TDC reverses, at least in part, the damage associated with experimental periodontitis. We look forward to continuing our work with Imagenetix as they move towards the path of a new drug application (NDA) and progressive drug development with the FDA.”

Commenting on the results of the study, Mr. William P. Spencer, President of Imagenetix said, “1-TDC is a promising early stage drug for the treatment of periodontitis. We now have two published animal studies showing clear evidence of efficacy and we continue to position our 1-TDC for a phase 1 trial with the FDA. In addition, we anticipate receiving news shortly on our patent associated with this compound. We also have contracted with an internationally respected Clinical Research Organization (CRO) to provide Imagenetix specific time lines to achieve drug approval from the FDA.”

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away®-Celadrin®. Please visit, www.celadrin.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company’s products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company’s SEC filings, including its Form 10-K for the year ended March 31, 2009.

SAN DIEGO, March 19 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today that Director of Research and Development, Dr. Robert Hesslink, presented basic research outlining the cellular pathway instrumental in the efficacy of Celadrin®. Dr. Hesslink outlined the pathway before an audience of scientists and industry leaders at the Nutrigenomics 2008 meeting in Paris, France. The meeting was sponsored by the International Society of Antioxidant in Nutrition and Health and held at the prestigious Universite Paris V, Faculte de Medecine Paris Descartes.

The clinical efficacy of Celadrin® has been published in such esteemed journals as the Journal of Rheumatology and the Journal of Strength Conditioning and Research. It has been shown that Celadrin® reduces joint and muscular discomfort within 30 minutes of topical application and within 14 days of oral consumption.

In Paris, Dr. Hesslink presented research from radio tracer label data and ligand binding assays supporting the hypothesis that Celadrin® interacts with membrane receptors involved with the inflammatory cascade. To support this hypothesis, Dr. Hesslink presented dual-label tracer data from the laboratory of Dr. Daniel Gallaher at the University of Minnesota showing the appearance of the labeled components of Celadrin® in the phospholipid fractions. The greatest amount of the label was found in the phospholipid fractions of liver homogenates (e.g. microsomes) and white blood cell microsomes.

In addition, Dr. Hesslink presented in vitro and binding assay studies conducted by a world leading clinical discovery organization for the pharmaceutical and biotechnology industries. In these in vitro studies, Celadrin® was shown to inhibit the thromboxane synthase enzyme using prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2) as substrates. Thromboxane is a very strong facilitator of inflammation and local tissue damage through a variety of mechanisms. To further elucidate the mechanism of action on thromboxane production, receptor binding assays were carried out on the thromboxane A2 membrane receptor. Celadrin® was found to exert strong receptor binding inhibition using a standard radio binding assay.

“The appearance of labeled Celadrin® within cellular membranes, especially those of the white blood cells coupled with inhibition of thromboxane production or receptor inhibition suggests that Celadrin® influences the prostaglandin cascade and resulting inflammation,” stated Dr. Hesslink. “It is this cellular data along with our safety and clinical efficacy data which provided the International Federation of Sports Medicine (FIMS) Executive Committee the confidence to select Celadrin® Topical Cream as FIMS’ first and only Official Pain Relieving Cream.”

Commenting on the presentation, Mr. William Spencer, Imagenetix’s Chief Executive Officer said, “We have completed a number of clinical studies which have demonstrated the effectiveness of Celadrin® in both capsule and topical delivery methods. These additional studies were conducted to determine how these results are achieved. We are pleased at the reaction of scientists to this presentation and with the acceptance of Celadrin® within the international community. Our international distribution partners are experiencing increased sales as their consumers see the benefits of Celadrin®. Dr. Hesslink and his team have put together an impressive portfolio of research documenting the safety and efficacy of Celadrin®.”

About ISANH

The aim of ISANH is to advance the practical applications of antioxidants, in all related fields, with particular reference to health and nutrition, and provide recommendations to ISANH’s members, health decision makers and institutions about the last antioxidant trends, uses and problems. In addition, ISANH encourages communication and interaction among researchers, physicians, nutritionists, industrials, food technology and strategic marketing managers through a global antioxidants network, please visit www.isanh.com.

About FIMS

The Federation Internationale de Medecine du Sports (FIMS)/International Federation of Sports Medicine is an international organization comprised of individual members, national associations, and multinational groups, with a common involvement with sports medicine on all continents. FIMS aims primarily to promote the study and development of sports medicine throughout the world, to assist athletes in achieving optimal performance, and to enhance health through the practice of exercise and physical activity in the general population. http://www.fims.org/.

SAN DIEGO, Feb. 25 /PRNewswire/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today that the International Federation of Sports Medicine (FIMS) and its Executive Committee has selected Celadrin® Topical Cream as its Official Pain Relieving Cream. FIMS’s goal since 1928 was to provide the best medical care for the athletes of the summer and winter Olympic Games. Now it has expanded its goal to provide the most advanced knowledge and technologies in sports medicine for world class athletes and exercise enthusiasts.

Commenting on the recommendation, Mr. William Spencer, Imagenetix’s Chief Executive Officer said, “We are extremely excited to have our Inflame Away®- Celadrin® selected by this World Class organization. FIMS consists of national associations of top sports medicine physicians, specialists and researchers and their endorsement is indicative of the strong science surrounding the product and the effective results the product has produced in athletes. The highly compelling scientific data from clinical trials in the area of pain management and reduction of inflammation was key to their recommendation.”

Celadrin® has been endorsed by FIMS as the official pain relieving cream for a period encompassing the years 2008 until 2012. Celadrin® will maintain this exclusive and prestigious association throughout this athletic cycle.

Mr. Spencer added, “We believe this endorsement will be instrumental in our retail launch of our branded product and will be the cornerstone of an advertising program utilizing testimonials of athletes alike that have used and endorse the product.”

Dr. Walter Frontera, the president of FIMS, stated that “FIMS is very impressed with the scientifically validated Celadrin® Topical Pain Cream. After reviewing the scientific attributes of Celadrin® Topical Pain Cream, FIMS is convinced of its efficacy for the treatment of soft tissue injuries that may interfere with sports performance.”

About FIMS

The Federation Internationale de Medecine du Sports (FIMS)/International Federation of Sports Medicine is an international organization comprised of individual members, national associations, and multinational groups, with a common involvement with sports medicine on all continents. FIMS aims primarily to promote the study and development of sports medicine throughout the world, to assist athletes in achieving optimal performance, and to enhance health through the practice of exercise and physical activity in the general population. http://www.fims.org/.

SAN DIEGO, Oct. 9 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today the appointment of Dr. Thomas Van Dyke to its Medical Advisory Board. Dr. Van Dyke will provide guidance to Imagenetix on their experimental compound, 1-TDC, for the treatment and prevention of periodontal disease. Dr. Van Dyke is Professor, Department of Periodontology and Oral Biology, Boston University Goldman School of Dental Medicine.

Dr. Van Dyke has extensive experience as a consultant to medical advisory boards having participated on boards spanning the spectrum from start-up to major pharmaceutical companies in the industry. In addition, he has participated as an investigator in numerous clinical trails of products seeking FDA approval.

Dr. Van Dyke received his D.D.S. (1973) from Case Western Reserve University; M.S. (1979) from SUNY at Buffalo in Oral Sciences and his Ph.D. (1982) from SUNY at Buffalo in Oral Biology. He is a Diplomate of the American Board of Periodontology (1989), and he received the IADR Award for Basic Research in Periodontology in 2001 and the Norton Ross Award for Excellence in Clinical Research in 2002. He serves on the editorial boards of Infection and Immunity (1989-present); Journal of Periodontology (1988-present), Journal of Periodontal Research (1987-present); Journal of Clinical Periodontology (1991- 1995), Journal of Public Health Dentistry (1991-1995), Current Opinions in Periodontology (1993). He served as President of the Periodontal Diseases Research Group of the IADR from 1991-1992. Dr. Van Dyke has authored/co- authored 200+ original articles, and numerous abstracts and book chapters. He is a member of the American/International Association of Dental Research, American Academy of Periodontology, American Dental Association, and a Diplomate of the American Board of Periodontology. His research interests are the structural and functional relationship of abnormalities of the inflammatory process with focus on regulation of phagocytic cells, in the etiology and pathogenesis of periodontal diseases. He is best known for his work on the pathways of resolution of inflammation and pathogenesis of periodontal diseases, neutrophil biology, and clinical research.

“We are very excited to add an individual of Dr. Van Dyke’s caliber and experience to our Medical Advisory Board”, said Mr. William Spencer, President of Imagenetix. “We believe his joining our Medical Advisory Board validates the success of our periodontal studies at Boston University. We also believe that he will be instrumental in helping us through the FDA process for our periodontal compound 1-TDC which we feel could be a major breakthrough in prevention of periodontal disease.”

Expects To See Substantial Sales Growth Balance of Year

SAN DIEGO, Aug. 17 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), will present at the Noble Financial Equity Conference at 11:30 a.m. EDT on Tuesday, August 21, 2007 at the Charleston Place Hotel in Charleston, South Carolina.

William Spencer, Imagenetix’s Chief Executive Officer will provide a 25 minute presentation outlining the science, products, and prospects for the Company. Commenting on the prospects, Mr. Spencer said, “I believe that the imminent publication of our most recent clinical study, for our Celadrin product, will lead to significant growth in our private label and branding business. Our distributor is negotiating with several large multinational companies for sale of the private label products, particularly in the International Market. We expect these sales in addition to our growth in retail sales to generate substantial growth in sales during the balance of the year.”

The presentation with streaming video and PowerPoint, will be webcast live on Noble Financial’s conference website at www.two-007.net. It is recommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access.

• Net Sales Increase 21%
• Gross Margins Improve 6%
• EPS $(0.04) verse $(0.04)
• Sees Significant Growth in Sales for Balance of Year

SAN DIEGO, Calif., Aug. 14 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), today reported results for its first fiscal quarter ended June 30, 2007. Net sales increased 21% to $1,126,991 from the $931,569 reported for the same period of the prior fiscal year. Gross profit as a percent of sales increased to 52% from 46% in the same period of the prior fiscal year.

For the quarter the operating loss increased to $(664,143) from $(434,532). Included in the results for the period was $305,000 of non cash expenses associated with the issuance of warrants and stock options. In addition during the period $204,000 was paid for advertising to support the retail launch.

Net loss for the period was $(435,526) or $(0.04) per share compared to $(377,837) or $(0.04) per share for the same period in the prior fiscal year. As of June 30, 2007 the Company has cash and cash equivalents of $1,545,483.

Commenting on the results for the quarter Mr. William Spencer, Imagenetix’s Chief Executive Officer said, “During the first quarter we have increased the number stores carrying our first branded product, Inflame Away(TM), to over 10,000. Towards the end of the quarter we began advertising to support our retail launch and have added another 1,000 stores which will begin to carry this product by the end of our second fiscal quarter. We are expecting to see a healthy increase in sales and margins as the retail launch accelerates.”

Mr. Spencer added, “Currently, our branded products being sold at Costco Online include Inflame Away(TM), our pain relieving cream, and Moractives(TM), Daily Vegetables and Daily Fruits and Berries. We will begin the retail launch of Moractives(TM) before the end of 2007.”

“In addition to our branded products we are making substantial progress in the private label area. We are also in negotiations with companies to develop programs to introduce our products world-wide. We are all very excited about the future for this Company. I expect to report continued sales increases for the remainder of our fiscal year.”

• Fourth Quarter Revenues Increases More Than 120% From Prior Year
• Fourth Quarter Net Income Before Tax $107,000 Versus Loss of $990,000 in Same Period Last Year
• Sees Solid Gains in Sales and Profits in Fiscal 2008

SAN DIEGO, June 28 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today results for its fourth fiscal quarter and fiscal year ended March 31, 2007. Net sales for the quarter were $2,270,000 an increase of 122% from the $1,021,000 reported for the same period of the prior fiscal year. Net sales for the fourth fiscal quarter also increased by 114% from the previous quarter ended December 31, 2006.

For the year net sales decreased by 26.8% to $5,597,000 from $7,650,000 reported in the prior fiscal year. For the full year gross margins were 47% compared to 46% for the prior fiscal year.

Net income before tax for the fourth fiscal quarter increased to $107,000 from the loss of ($990,000) incurred during the same quarter of the prior fiscal year. For the year the net loss before tax was ($806,000) compared to ($1,217,000) in the prior fiscal year.

Net loss for the year was ($667,000) or $(.06) per share compared to a loss of ($593, 000) or $(.06) per share incurred in the prior fiscal year.

As of March 31, 2007 the Company had a cash balance of $959,000, a current ratio of 7 to 1 with current assets of $4,583,000 and current liabilities of $651,000. Long term debt was reduced to $37,000.

Commenting on the results for the year Mr. William Spencer, Imagenetix’s Chief Executive Officer said, “Fiscal 2007 was a transitional year for the Company. I am pleased with the results, particularly of those achieved during our fourth quarter where we returned to profitability.

During the year we began for the first time to sell our own branded products to the mass markets. We are now in over 10,000 locations for our Inflame Away (TM) products and have recently begun an advertising program to support the retail launch.

Our second group of branded products, Moractives (TM), Daily Vegetables and Daily Fruits and Berries are now being sold at Costco Online and we expect to begin distribution into the mass market in the fall of this year.

During the year we have made substantial progress in the development of our proprietary compound 1-TDC for the prevention and treatment of periodontal disease. We have completed two successful studies at Boston University; results of the first have been recently published in The Journal of Periodontology. We are now in the process of determining the process to begin an FDA submission for the product which we believe can be a major breakthrough.

I am excited about the prospects for Imagenetix and believe we will continue to see growth during fiscal 2008 with solid gains in sales, gross margins and profits.”